Thelansis

Beta-Thalassemia Market Outlook Thelansis’s “Beta-Thalassemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Beta-Thalassemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights...

Beta-Thalassemia Market Outlook Thelansis’s “Beta-Thalassemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Beta-Thalassemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Beta-Thalassemia Overview Beta-thalassemia (BT) is a genetic disorder characterized by a deficiency (Beta+) or absence (Beta0) of the beta-globin chains of hemoglobin (Hb). There are three main types of BT: BT-minor, BT-major, and BT-intermedia. BT-minor is the heterozygous form and is generally asymptomatic. At the same time, BT-major is the homozygous form that causes splenomegaly, microcytic, and hypochromic anemia and requires systematic transfusions t...

 Beta-thalassemia (BT) is a genetic disorder characterized by a deficiency (Beta+) or absence (Beta0) of the beta-globin chains of hemoglobin (Hb). There are three main types of BT: BT-minor, BT-major, and BT-intermedia. BT-minor is the heterozygous form and is generally asymptomatic. At the same time, BT-major is the homozygous form that causes splenomegaly, microcytic and hypochromic anemia, and requires systematic transfusions to maintain Hb levels above 90-100 g/L. Long-term transfusion results in iron overload, which can cause significant morbidity and hamper the vital prognosis. BT-intermedia is less severe than BT-major and diagnosed later in life, and patients may or may not require occasional transfusions. Diagnosis of BT relies on analyzing Hb by electrophoresis or HPLC. Treatment options for BT include a combination of regular transfusions and iron chelation therapy, which has led to increased survival during the last 40 years. The prognosis depends on the severity of th...